nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—systemic lupus erythematosus	0.286	1	CbGaD
Lenalidomide—PTGS2—Dapsone—systemic lupus erythematosus	0.0753	0.195	CbGbCtD
Lenalidomide—PTGS2—Triamcinolone—systemic lupus erythematosus	0.0653	0.169	CbGbCtD
Lenalidomide—PTGS2—Betamethasone—systemic lupus erythematosus	0.056	0.145	CbGbCtD
Lenalidomide—PTGS2—Dexamethasone—systemic lupus erythematosus	0.0326	0.0844	CbGbCtD
Lenalidomide—ABCB1—Methylprednisolone—systemic lupus erythematosus	0.0284	0.0736	CbGbCtD
Lenalidomide—ABCB1—Mycophenolate mofetil—systemic lupus erythematosus	0.0216	0.0558	CbGbCtD
Lenalidomide—ABCB1—Betamethasone—systemic lupus erythematosus	0.0185	0.0479	CbGbCtD
Lenalidomide—ABCB1—Prednisolone—systemic lupus erythematosus	0.0182	0.0472	CbGbCtD
Lenalidomide—ABCB1—Hydrocortisone—systemic lupus erythematosus	0.0173	0.0448	CbGbCtD
Lenalidomide—ABCB1—Prednisone—systemic lupus erythematosus	0.0172	0.0446	CbGbCtD
Lenalidomide—ABCB1—Cyclosporine—systemic lupus erythematosus	0.0163	0.0423	CbGbCtD
Lenalidomide—ABCB1—Dexamethasone—systemic lupus erythematosus	0.0108	0.0278	CbGbCtD
Lenalidomide—ABCB1—Methotrexate—systemic lupus erythematosus	0.00864	0.0224	CbGbCtD
Lenalidomide—CDH5—endothelium—systemic lupus erythematosus	0.00774	0.112	CbGeAlD
Lenalidomide—TNFSF11—connective tissue—systemic lupus erythematosus	0.00486	0.0707	CbGeAlD
Lenalidomide—CDH5—connective tissue—systemic lupus erythematosus	0.00366	0.0532	CbGeAlD
Lenalidomide—TNFSF11—lymphoid tissue—systemic lupus erythematosus	0.00355	0.0517	CbGeAlD
Lenalidomide—TNFSF11—tendon—systemic lupus erythematosus	0.00334	0.0486	CbGeAlD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—TRAF1—systemic lupus erythematosus	0.00331	0.0866	CbGpPWpGaD
Lenalidomide—TNFSF11—bone marrow—systemic lupus erythematosus	0.00324	0.047	CbGeAlD
Lenalidomide—CDH5—cortex of kidney—systemic lupus erythematosus	0.00303	0.0441	CbGeAlD
Lenalidomide—TNFSF11—lung—systemic lupus erythematosus	0.00293	0.0426	CbGeAlD
Lenalidomide—CDH5—lymphoid tissue—systemic lupus erythematosus	0.00267	0.0389	CbGeAlD
Lenalidomide—CDH5—tendon—systemic lupus erythematosus	0.00251	0.0365	CbGeAlD
Lenalidomide—CDH5—bone marrow—systemic lupus erythematosus	0.00244	0.0354	CbGeAlD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—LYN—systemic lupus erythematosus	0.00239	0.0625	CbGpPWpGaD
Lenalidomide—CRBN—nephron tubule—systemic lupus erythematosus	0.00225	0.0327	CbGeAlD
Lenalidomide—CDH5—lung—systemic lupus erythematosus	0.00221	0.0321	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—JUNB—systemic lupus erythematosus	0.00214	0.056	CbGpPWpGaD
Lenalidomide—CDH5—nervous system—systemic lupus erythematosus	0.00204	0.0297	CbGeAlD
Lenalidomide—CDH5—central nervous system—systemic lupus erythematosus	0.00197	0.0286	CbGeAlD
Lenalidomide—CRBN—cortex of kidney—systemic lupus erythematosus	0.00193	0.028	CbGeAlD
Lenalidomide—Pomalidomide—TNF—systemic lupus erythematosus	0.00192	0.412	CrCbGaD
Lenalidomide—CRBN—lymphoid tissue—systemic lupus erythematosus	0.0017	0.0247	CbGeAlD
Lenalidomide—CRBN—tendon—systemic lupus erythematosus	0.0016	0.0232	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—JAK1—systemic lupus erythematosus	0.00158	0.0412	CbGpPWpGaD
Lenalidomide—CRBN—bone marrow—systemic lupus erythematosus	0.00155	0.0225	CbGeAlD
Lenalidomide—CRBN—lung—systemic lupus erythematosus	0.0014	0.0204	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—CRP—systemic lupus erythematosus	0.00139	0.0363	CbGpPWpGaD
Lenalidomide—PTGS2—endothelium—systemic lupus erythematosus	0.00134	0.0194	CbGeAlD
Lenalidomide—CRBN—nervous system—systemic lupus erythematosus	0.0013	0.0189	CbGeAlD
Lenalidomide—CRBN—central nervous system—systemic lupus erythematosus	0.00125	0.0182	CbGeAlD
Lenalidomide—Thalidomide—TNF—systemic lupus erythematosus	0.00124	0.266	CrCbGaD
Lenalidomide—PTGS2—blood plasma—systemic lupus erythematosus	0.00119	0.0173	CbGeAlD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—NOS3—systemic lupus erythematosus	0.00117	0.0306	CbGpPWpGaD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—ANXA3—systemic lupus erythematosus	0.00108	0.0282	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NCF2—systemic lupus erythematosus	0.00107	0.028	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—TYK2—systemic lupus erythematosus	0.00104	0.0271	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—NCF2—systemic lupus erythematosus	0.00101	0.0264	CbGpPWpGaD
Lenalidomide—Pomalidomide—PTGS2—systemic lupus erythematosus	0.000911	0.196	CrCbGaD
Lenalidomide—ABCB1—blood plasma—systemic lupus erythematosus	0.000735	0.0107	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—VEGFA—systemic lupus erythematosus	0.000721	0.0189	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—TGFB1—systemic lupus erythematosus	0.000662	0.0173	CbGpPWpGaD
Lenalidomide—PTGS2—connective tissue—systemic lupus erythematosus	0.000633	0.00919	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—JAK1—systemic lupus erythematosus	0.000619	0.0162	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IKZF1—systemic lupus erythematosus	0.000594	0.0155	CbGpPWpGaD
Lenalidomide—Thalidomide—PTGS2—systemic lupus erythematosus	0.000587	0.126	CrCbGaD
Lenalidomide—CDH5—Signaling by VEGF—JAK1—systemic lupus erythematosus	0.000584	0.0153	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic lupus erythematosus	0.000574	0.015	CbGpPWpGaD
Lenalidomide—PTGS2—skin of body—systemic lupus erythematosus	0.000571	0.0083	CbGeAlD
Lenalidomide—PTGS2—kidney—systemic lupus erythematosus	0.000539	0.00783	CbGeAlD
Lenalidomide—PTGS2—Fluocinonide—Methylprednisolone—systemic lupus erythematosus	0.000529	0.159	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Betamethasone—systemic lupus erythematosus	0.00052	0.156	CbGdCrCtD
Lenalidomide—PTGS2—Fluocinonide—Dexamethasone—systemic lupus erythematosus	0.00052	0.156	CbGdCrCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—PRTN3—systemic lupus erythematosus	0.000517	0.0135	CbGpPWpGaD
Lenalidomide—PTGS2—Fluocinonide—Triamcinolone—systemic lupus erythematosus	0.000508	0.153	CbGdCrCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6—systemic lupus erythematosus	0.000507	0.0133	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6—systemic lupus erythematosus	0.000499	0.0131	CbGpPWpGaD
Lenalidomide—PTGS2—lymphoid tissue—systemic lupus erythematosus	0.000463	0.00672	CbGeAlD
Lenalidomide—PTGS2—Spinal Cord Injury—TNFSF13B—systemic lupus erythematosus	0.000442	0.0116	CbGpPWpGaD
Lenalidomide—PTGS2—tendon—systemic lupus erythematosus	0.000435	0.00632	CbGeAlD
Lenalidomide—ABCB1—Allograft Rejection—IL21—systemic lupus erythematosus	0.000432	0.0113	CbGpPWpGaD
Lenalidomide—PTGS2—bone marrow—systemic lupus erythematosus	0.000421	0.00612	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—systemic lupus erythematosus	0.000414	0.0108	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—TYK2—systemic lupus erythematosus	0.000407	0.0107	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NOS3—systemic lupus erythematosus	0.000399	0.0105	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—TYK2—systemic lupus erythematosus	0.000384	0.0101	CbGpPWpGaD
Lenalidomide—PTGS2—lung—systemic lupus erythematosus	0.000382	0.00555	CbGeAlD
Lenalidomide—ABCB1—nephron tubule—systemic lupus erythematosus	0.000379	0.00551	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—NOS3—systemic lupus erythematosus	0.000377	0.00987	CbGpPWpGaD
Lenalidomide—PTGS2—nervous system—systemic lupus erythematosus	0.000353	0.00514	CbGeAlD
Lenalidomide—PTGS2—central nervous system—systemic lupus erythematosus	0.00034	0.00494	CbGeAlD
Lenalidomide—ABCB1—kidney—systemic lupus erythematosus	0.000333	0.00484	CbGeAlD
Lenalidomide—ABCB1—cortex of kidney—systemic lupus erythematosus	0.000324	0.00472	CbGeAlD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUNB—systemic lupus erythematosus	0.000322	0.00842	CbGpPWpGaD
Lenalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—systemic lupus erythematosus	0.000319	0.0958	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—systemic lupus erythematosus	0.000314	0.0943	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Betamethasone—systemic lupus erythematosus	0.000314	0.0943	CbGdCrCtD
Lenalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—systemic lupus erythematosus	0.000307	0.0921	CbGdCrCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—systemic lupus erythematosus	0.0003	0.00786	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CRP—systemic lupus erythematosus	0.000293	0.00767	CbGpPWpGaD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—PRL—systemic lupus erythematosus	0.000289	0.00755	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VEGFA—systemic lupus erythematosus	0.000288	0.00753	CbGpPWpGaD
Lenalidomide—ABCB1—lymphoid tissue—systemic lupus erythematosus	0.000286	0.00416	CbGeAlD
Lenalidomide—ABCB1—Drug Induction of Bile Acid Pathway—VDR—systemic lupus erythematosus	0.000278	0.00726	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—VEGFA—systemic lupus erythematosus	0.000272	0.00711	CbGpPWpGaD
Lenalidomide—ABCB1—bone marrow—systemic lupus erythematosus	0.000261	0.00379	CbGeAlD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic lupus erythematosus	0.000248	0.0065	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—systemic lupus erythematosus	0.000242	0.00632	CbGpPWpGaD
Lenalidomide—ABCB1—lung—systemic lupus erythematosus	0.000236	0.00343	CbGeAlD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—FASLG—systemic lupus erythematosus	0.000231	0.00604	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—systemic lupus erythematosus	0.000221	0.00579	CbGpPWpGaD
Lenalidomide—ABCB1—nervous system—systemic lupus erythematosus	0.000219	0.00318	CbGeAlD
Lenalidomide—ABCB1—Allograft Rejection—C4A—systemic lupus erythematosus	0.000211	0.00552	CbGpPWpGaD
Lenalidomide—ABCB1—central nervous system—systemic lupus erythematosus	0.00021	0.00306	CbGeAlD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUNB—systemic lupus erythematosus	0.000208	0.00545	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic lupus erythematosus	0.000207	0.00541	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—systemic lupus erythematosus	0.000199	0.00521	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNFSF13—systemic lupus erythematosus	0.000193	0.00504	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—LYN—systemic lupus erythematosus	0.00019	0.00497	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—IL6—systemic lupus erythematosus	0.000188	0.00492	CbGpPWpGaD
Lenalidomide—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—systemic lupus erythematosus	0.000185	0.00484	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—systemic lupus erythematosus	0.000178	0.00465	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—ETS1—systemic lupus erythematosus	0.000171	0.00447	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic lupus erythematosus	0.000161	0.00421	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—systemic lupus erythematosus	0.000159	0.00417	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—GADD45A—systemic lupus erythematosus	0.000159	0.00416	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—systemic lupus erythematosus	0.000156	0.00409	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—systemic lupus erythematosus	0.000155	0.00405	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—systemic lupus erythematosus	0.000149	0.00391	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FOXP3—systemic lupus erythematosus	0.000148	0.00386	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—ETS1—systemic lupus erythematosus	0.000147	0.00384	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—systemic lupus erythematosus	0.000146	0.00382	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—systemic lupus erythematosus	0.000143	0.00375	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—systemic lupus erythematosus	0.000133	0.00347	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—FCGR2A—systemic lupus erythematosus	0.000131	0.00342	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—systemic lupus erythematosus	0.00013	0.0034	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TLR9—systemic lupus erythematosus	0.000128	0.00336	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—P2RY12—systemic lupus erythematosus	0.000124	0.00325	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—CXCL12—systemic lupus erythematosus	0.00012	0.00315	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HIST2H2AC—systemic lupus erythematosus	0.000117	0.00307	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL17A—systemic lupus erythematosus	0.000116	0.00304	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—systemic lupus erythematosus	0.000115	0.00301	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CSK—systemic lupus erythematosus	0.000114	0.00299	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—systemic lupus erythematosus	0.000111	0.00291	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—GADD45A—systemic lupus erythematosus	0.000111	0.00291	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL12B—systemic lupus erythematosus	0.000108	0.00283	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—systemic lupus erythematosus	0.000107	0.0028	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NCF2—systemic lupus erythematosus	0.000105	0.00274	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CXCL12—systemic lupus erythematosus	0.000104	0.00273	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LYN—systemic lupus erythematosus	0.000104	0.00272	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD40—systemic lupus erythematosus	0.000103	0.0027	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SH2B3—systemic lupus erythematosus	0.000102	0.00267	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CTLA4—systemic lupus erythematosus	0.000102	0.00266	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—systemic lupus erythematosus	9.45e-05	0.00247	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—systemic lupus erythematosus	9.17e-05	0.0024	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DQA1—systemic lupus erythematosus	8.94e-05	0.00234	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CRP—systemic lupus erythematosus	8.6e-05	0.00225	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—systemic lupus erythematosus	8.47e-05	0.00222	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—systemic lupus erythematosus	8.4e-05	0.0022	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DQB1—systemic lupus erythematosus	8.37e-05	0.00219	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCL12—systemic lupus erythematosus	8.37e-05	0.00219	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—JUNB—systemic lupus erythematosus	8.21e-05	0.00215	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EP300—systemic lupus erythematosus	8.05e-05	0.00211	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—F2—systemic lupus erythematosus	7.93e-05	0.00208	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD40LG—systemic lupus erythematosus	7.9e-05	0.00207	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL10—systemic lupus erythematosus	7.9e-05	0.00207	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL4—systemic lupus erythematosus	7.87e-05	0.00206	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RASGRP1—systemic lupus erythematosus	7.8e-05	0.00204	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL4—systemic lupus erythematosus	7.69e-05	0.00201	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—systemic lupus erythematosus	7.63e-05	0.002	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PRL—systemic lupus erythematosus	7.57e-05	0.00198	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—systemic lupus erythematosus	7.55e-05	0.00198	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FASLG—systemic lupus erythematosus	7.34e-05	0.00192	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUNB—systemic lupus erythematosus	7.12e-05	0.00186	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FAS—systemic lupus erythematosus	7.08e-05	0.00185	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CCL2—systemic lupus erythematosus	7.07e-05	0.00185	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL2RA—systemic lupus erythematosus	7.04e-05	0.00184	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—C3—systemic lupus erythematosus	6.98e-05	0.00183	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC15A4—systemic lupus erythematosus	6.9e-05	0.00181	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ALB—systemic lupus erythematosus	6.59e-05	0.00172	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—systemic lupus erythematosus	6.54e-05	0.00171	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TLR4—systemic lupus erythematosus	6.52e-05	0.00171	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DRB1—systemic lupus erythematosus	6.36e-05	0.00166	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—systemic lupus erythematosus	6.24e-05	0.00163	CbGpPWpGaD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—systemic lupus erythematosus	6.18e-05	0.00162	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—systemic lupus erythematosus	6.12e-05	0.0016	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—JAK1—systemic lupus erythematosus	6.05e-05	0.00158	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CD4—systemic lupus erythematosus	6.03e-05	0.00158	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IFNG—systemic lupus erythematosus	6.01e-05	0.00157	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CD80—systemic lupus erythematosus	5.88e-05	0.00154	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCR5—systemic lupus erythematosus	5.73e-05	0.0015	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN1B—systemic lupus erythematosus	5.67e-05	0.00148	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL2RA—systemic lupus erythematosus	5.65e-05	0.00148	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—C3—systemic lupus erythematosus	5.6e-05	0.00147	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCL2—systemic lupus erythematosus	5.59e-05	0.00146	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—systemic lupus erythematosus	5.35e-05	0.0014	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN1A—systemic lupus erythematosus	5.23e-05	0.00137	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—systemic lupus erythematosus	5.11e-05	0.00134	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—systemic lupus erythematosus	5.05e-05	0.00132	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—EP300—systemic lupus erythematosus	4.98e-05	0.0013	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—systemic lupus erythematosus	4.93e-05	0.00129	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—F2—systemic lupus erythematosus	4.92e-05	0.00129	CbGpPWpGaD
Lenalidomide—Vision blurred—Prednisone—systemic lupus erythematosus	4.89e-05	0.00023	CcSEcCtD
Lenalidomide—Urethral disorder—Methotrexate—systemic lupus erythematosus	4.88e-05	0.00023	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Triamcinolone—systemic lupus erythematosus	4.88e-05	0.00023	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Methylprednisolone—systemic lupus erythematosus	4.87e-05	0.000229	CcSEcCtD
Lenalidomide—Pain—Hydrocortisone—systemic lupus erythematosus	4.87e-05	0.000229	CcSEcCtD
Lenalidomide—Oedema—Dexamethasone—systemic lupus erythematosus	4.86e-05	0.000229	CcSEcCtD
Lenalidomide—Oedema—Betamethasone—systemic lupus erythematosus	4.86e-05	0.000229	CcSEcCtD
Lenalidomide—Insomnia—Triamcinolone—systemic lupus erythematosus	4.85e-05	0.000228	CcSEcCtD
Lenalidomide—Insomnia—Methylprednisolone—systemic lupus erythematosus	4.84e-05	0.000228	CcSEcCtD
Lenalidomide—Infection—Dexamethasone—systemic lupus erythematosus	4.83e-05	0.000227	CcSEcCtD
Lenalidomide—Infection—Betamethasone—systemic lupus erythematosus	4.83e-05	0.000227	CcSEcCtD
Lenalidomide—Ill-defined disorder—Prednisone—systemic lupus erythematosus	4.81e-05	0.000227	CcSEcCtD
Lenalidomide—Paraesthesia—Triamcinolone—systemic lupus erythematosus	4.81e-05	0.000227	CcSEcCtD
Lenalidomide—Feeling abnormal—Prednisolone—systemic lupus erythematosus	4.8e-05	0.000226	CcSEcCtD
Lenalidomide—Paraesthesia—Methylprednisolone—systemic lupus erythematosus	4.8e-05	0.000226	CcSEcCtD
Lenalidomide—Visual impairment—Methotrexate—systemic lupus erythematosus	4.8e-05	0.000226	CcSEcCtD
Lenalidomide—Anaemia—Prednisone—systemic lupus erythematosus	4.8e-05	0.000226	CcSEcCtD
Lenalidomide—Shock—Betamethasone—systemic lupus erythematosus	4.78e-05	0.000225	CcSEcCtD
Lenalidomide—Shock—Dexamethasone—systemic lupus erythematosus	4.78e-05	0.000225	CcSEcCtD
Lenalidomide—Dyspnoea—Triamcinolone—systemic lupus erythematosus	4.78e-05	0.000225	CcSEcCtD
Lenalidomide—Nervous system disorder—Dexamethasone—systemic lupus erythematosus	4.77e-05	0.000225	CcSEcCtD
Lenalidomide—Nervous system disorder—Betamethasone—systemic lupus erythematosus	4.77e-05	0.000225	CcSEcCtD
Lenalidomide—Agitation—Prednisone—systemic lupus erythematosus	4.77e-05	0.000225	CcSEcCtD
Lenalidomide—Thrombocytopenia—Betamethasone—systemic lupus erythematosus	4.76e-05	0.000224	CcSEcCtD
Lenalidomide—Thrombocytopenia—Dexamethasone—systemic lupus erythematosus	4.76e-05	0.000224	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IFNG—systemic lupus erythematosus	4.75e-05	0.00124	CbGpPWpGaD
Lenalidomide—Tachycardia—Betamethasone—systemic lupus erythematosus	4.75e-05	0.000223	CcSEcCtD
Lenalidomide—Tachycardia—Dexamethasone—systemic lupus erythematosus	4.75e-05	0.000223	CcSEcCtD
Lenalidomide—Angioedema—Prednisone—systemic lupus erythematosus	4.74e-05	0.000223	CcSEcCtD
Lenalidomide—Hypersensitivity—Cyclosporine—systemic lupus erythematosus	4.72e-05	0.000222	CcSEcCtD
Lenalidomide—Dyspepsia—Triamcinolone—systemic lupus erythematosus	4.72e-05	0.000222	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CD80—systemic lupus erythematosus	4.72e-05	0.00123	CbGpPWpGaD
Lenalidomide—Erythema multiforme—Methotrexate—systemic lupus erythematosus	4.71e-05	0.000222	CcSEcCtD
Lenalidomide—Dyspepsia—Methylprednisolone—systemic lupus erythematosus	4.71e-05	0.000222	CcSEcCtD
Lenalidomide—Hyperhidrosis—Dexamethasone—systemic lupus erythematosus	4.7e-05	0.000221	CcSEcCtD
Lenalidomide—Hyperhidrosis—Betamethasone—systemic lupus erythematosus	4.7e-05	0.000221	CcSEcCtD
Lenalidomide—Feeling abnormal—Hydrocortisone—systemic lupus erythematosus	4.69e-05	0.000221	CcSEcCtD
Lenalidomide—Malaise—Prednisone—systemic lupus erythematosus	4.68e-05	0.00022	CcSEcCtD
Lenalidomide—Vertigo—Prednisone—systemic lupus erythematosus	4.66e-05	0.000219	CcSEcCtD
Lenalidomide—Eye disorder—Methotrexate—systemic lupus erythematosus	4.66e-05	0.000219	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Hydrocortisone—systemic lupus erythematosus	4.65e-05	0.000219	CcSEcCtD
Lenalidomide—Syncope—Prednisone—systemic lupus erythematosus	4.65e-05	0.000219	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IFNG—systemic lupus erythematosus	4.65e-05	0.00122	CbGpPWpGaD
Lenalidomide—Tinnitus—Methotrexate—systemic lupus erythematosus	4.64e-05	0.000219	CcSEcCtD
Lenalidomide—Anorexia—Dexamethasone—systemic lupus erythematosus	4.64e-05	0.000218	CcSEcCtD
Lenalidomide—Anorexia—Betamethasone—systemic lupus erythematosus	4.64e-05	0.000218	CcSEcCtD
Lenalidomide—Urticaria—Prednisolone—systemic lupus erythematosus	4.63e-05	0.000218	CcSEcCtD
Lenalidomide—Cardiac disorder—Methotrexate—systemic lupus erythematosus	4.62e-05	0.000218	CcSEcCtD
Lenalidomide—Fatigue—Triamcinolone—systemic lupus erythematosus	4.62e-05	0.000218	CcSEcCtD
Lenalidomide—Fatigue—Methylprednisolone—systemic lupus erythematosus	4.61e-05	0.000217	CcSEcCtD
Lenalidomide—Hypersensitivity—Mycophenolate mofetil—systemic lupus erythematosus	4.6e-05	0.000217	CcSEcCtD
Lenalidomide—Asthenia—Cyclosporine—systemic lupus erythematosus	4.59e-05	0.000216	CcSEcCtD
Lenalidomide—Pain—Triamcinolone—systemic lupus erythematosus	4.58e-05	0.000216	CcSEcCtD
Lenalidomide—Loss of consciousness—Prednisone—systemic lupus erythematosus	4.56e-05	0.000215	CcSEcCtD
Lenalidomide—Hypotension—Betamethasone—systemic lupus erythematosus	4.54e-05	0.000214	CcSEcCtD
Lenalidomide—Hypotension—Dexamethasone—systemic lupus erythematosus	4.54e-05	0.000214	CcSEcCtD
Lenalidomide—Pruritus—Cyclosporine—systemic lupus erythematosus	4.53e-05	0.000213	CcSEcCtD
Lenalidomide—Urticaria—Hydrocortisone—systemic lupus erythematosus	4.52e-05	0.000213	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—systemic lupus erythematosus	4.52e-05	0.000213	CcSEcCtD
Lenalidomide—Immune system disorder—Methotrexate—systemic lupus erythematosus	4.5e-05	0.000212	CcSEcCtD
Lenalidomide—Abdominal pain—Hydrocortisone—systemic lupus erythematosus	4.5e-05	0.000212	CcSEcCtD
Lenalidomide—Body temperature increased—Hydrocortisone—systemic lupus erythematosus	4.5e-05	0.000212	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—systemic lupus erythematosus	4.49e-05	0.000211	CcSEcCtD
Lenalidomide—Asthenia—Mycophenolate mofetil—systemic lupus erythematosus	4.48e-05	0.000211	CcSEcCtD
Lenalidomide—Hypertension—Prednisone—systemic lupus erythematosus	4.48e-05	0.000211	CcSEcCtD
Lenalidomide—Chills—Methotrexate—systemic lupus erythematosus	4.47e-05	0.00021	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Betamethasone—systemic lupus erythematosus	4.43e-05	0.000209	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Dexamethasone—systemic lupus erythematosus	4.43e-05	0.000209	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—systemic lupus erythematosus	4.43e-05	0.00116	CbGpPWpGaD
Lenalidomide—Pruritus—Mycophenolate mofetil—systemic lupus erythematosus	4.42e-05	0.000208	CcSEcCtD
Lenalidomide—Myalgia—Prednisone—systemic lupus erythematosus	4.42e-05	0.000208	CcSEcCtD
Lenalidomide—Arthralgia—Prednisone—systemic lupus erythematosus	4.42e-05	0.000208	CcSEcCtD
Lenalidomide—Feeling abnormal—Triamcinolone—systemic lupus erythematosus	4.42e-05	0.000208	CcSEcCtD
Lenalidomide—Feeling abnormal—Methylprednisolone—systemic lupus erythematosus	4.41e-05	0.000207	CcSEcCtD
Lenalidomide—Anxiety—Prednisone—systemic lupus erythematosus	4.4e-05	0.000207	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—systemic lupus erythematosus	4.4e-05	0.000207	CcSEcCtD
Lenalidomide—Insomnia—Dexamethasone—systemic lupus erythematosus	4.4e-05	0.000207	CcSEcCtD
Lenalidomide—Insomnia—Betamethasone—systemic lupus erythematosus	4.4e-05	0.000207	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic lupus erythematosus	4.39e-05	0.000207	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CCL2—systemic lupus erythematosus	4.38e-05	0.00115	CbGpPWpGaD
Lenalidomide—Diarrhoea—Cyclosporine—systemic lupus erythematosus	4.38e-05	0.000206	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methylprednisolone—systemic lupus erythematosus	4.37e-05	0.000206	CcSEcCtD
Lenalidomide—Paraesthesia—Dexamethasone—systemic lupus erythematosus	4.37e-05	0.000206	CcSEcCtD
Lenalidomide—Paraesthesia—Betamethasone—systemic lupus erythematosus	4.37e-05	0.000206	CcSEcCtD
Lenalidomide—Discomfort—Prednisone—systemic lupus erythematosus	4.36e-05	0.000205	CcSEcCtD
Lenalidomide—Mental disorder—Methotrexate—systemic lupus erythematosus	4.36e-05	0.000205	CcSEcCtD
Lenalidomide—Erythema—Methotrexate—systemic lupus erythematosus	4.34e-05	0.000204	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—systemic lupus erythematosus	4.34e-05	0.000204	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CDKN1B—systemic lupus erythematosus	4.32e-05	0.00113	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Prednisolone—systemic lupus erythematosus	4.29e-05	0.000202	CcSEcCtD
Lenalidomide—Dyspepsia—Dexamethasone—systemic lupus erythematosus	4.28e-05	0.000202	CcSEcCtD
Lenalidomide—Dyspepsia—Betamethasone—systemic lupus erythematosus	4.28e-05	0.000202	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—EP300—systemic lupus erythematosus	4.28e-05	0.00112	CbGpPWpGaD
Lenalidomide—Diarrhoea—Mycophenolate mofetil—systemic lupus erythematosus	4.27e-05	0.000201	CcSEcCtD
Lenalidomide—Urticaria—Triamcinolone—systemic lupus erythematosus	4.26e-05	0.0002	CcSEcCtD
Lenalidomide—Urticaria—Methylprednisolone—systemic lupus erythematosus	4.25e-05	0.0002	CcSEcCtD
Lenalidomide—Dysgeusia—Methotrexate—systemic lupus erythematosus	4.25e-05	0.0002	CcSEcCtD
Lenalidomide—Body temperature increased—Triamcinolone—systemic lupus erythematosus	4.24e-05	0.000199	CcSEcCtD
Lenalidomide—Dizziness—Cyclosporine—systemic lupus erythematosus	4.23e-05	0.000199	CcSEcCtD
Lenalidomide—Oedema—Prednisone—systemic lupus erythematosus	4.23e-05	0.000199	CcSEcCtD
Lenalidomide—Abdominal pain—Methylprednisolone—systemic lupus erythematosus	4.23e-05	0.000199	CcSEcCtD
Lenalidomide—Decreased appetite—Betamethasone—systemic lupus erythematosus	4.23e-05	0.000199	CcSEcCtD
Lenalidomide—Decreased appetite—Dexamethasone—systemic lupus erythematosus	4.23e-05	0.000199	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—systemic lupus erythematosus	4.22e-05	0.00111	CbGpPWpGaD
Lenalidomide—Infection—Prednisone—systemic lupus erythematosus	4.21e-05	0.000198	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Betamethasone—systemic lupus erythematosus	4.2e-05	0.000198	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Dexamethasone—systemic lupus erythematosus	4.2e-05	0.000198	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—systemic lupus erythematosus	4.19e-05	0.000197	CcSEcCtD
Lenalidomide—Hypersensitivity—Hydrocortisone—systemic lupus erythematosus	4.19e-05	0.000197	CcSEcCtD
Lenalidomide—Fatigue—Dexamethasone—systemic lupus erythematosus	4.19e-05	0.000197	CcSEcCtD
Lenalidomide—Fatigue—Betamethasone—systemic lupus erythematosus	4.19e-05	0.000197	CcSEcCtD
Lenalidomide—Shock—Prednisone—systemic lupus erythematosus	4.17e-05	0.000196	CcSEcCtD
Lenalidomide—Pain—Dexamethasone—systemic lupus erythematosus	4.16e-05	0.000196	CcSEcCtD
Lenalidomide—Pain—Betamethasone—systemic lupus erythematosus	4.16e-05	0.000196	CcSEcCtD
Lenalidomide—Nervous system disorder—Prednisone—systemic lupus erythematosus	4.15e-05	0.000196	CcSEcCtD
Lenalidomide—Tachycardia—Prednisone—systemic lupus erythematosus	4.13e-05	0.000195	CcSEcCtD
Lenalidomide—Dizziness—Mycophenolate mofetil—systemic lupus erythematosus	4.13e-05	0.000195	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL2—systemic lupus erythematosus	4.13e-05	0.00108	CbGpPWpGaD
Lenalidomide—Skin disorder—Prednisone—systemic lupus erythematosus	4.11e-05	0.000194	CcSEcCtD
Lenalidomide—Hyperhidrosis—Prednisone—systemic lupus erythematosus	4.09e-05	0.000193	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—systemic lupus erythematosus	4.09e-05	0.000192	CcSEcCtD
Lenalidomide—Asthenia—Hydrocortisone—systemic lupus erythematosus	4.08e-05	0.000192	CcSEcCtD
Lenalidomide—Vomiting—Cyclosporine—systemic lupus erythematosus	4.07e-05	0.000192	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—systemic lupus erythematosus	4.05e-05	0.00106	CbGpPWpGaD
Lenalidomide—Rash—Cyclosporine—systemic lupus erythematosus	4.04e-05	0.00019	CcSEcCtD
Lenalidomide—Anorexia—Prednisone—systemic lupus erythematosus	4.04e-05	0.00019	CcSEcCtD
Lenalidomide—Dermatitis—Cyclosporine—systemic lupus erythematosus	4.03e-05	0.00019	CcSEcCtD
Lenalidomide—Pruritus—Hydrocortisone—systemic lupus erythematosus	4.03e-05	0.00019	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—systemic lupus erythematosus	4.02e-05	0.000189	CcSEcCtD
Lenalidomide—Headache—Cyclosporine—systemic lupus erythematosus	4.01e-05	0.000189	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—systemic lupus erythematosus	4.01e-05	0.000189	CcSEcCtD
Lenalidomide—Feeling abnormal—Betamethasone—systemic lupus erythematosus	4.01e-05	0.000189	CcSEcCtD
Lenalidomide—Feeling abnormal—Dexamethasone—systemic lupus erythematosus	4.01e-05	0.000189	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—systemic lupus erythematosus	4e-05	0.00105	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TYK2—systemic lupus erythematosus	3.98e-05	0.00104	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Dexamethasone—systemic lupus erythematosus	3.98e-05	0.000187	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Betamethasone—systemic lupus erythematosus	3.98e-05	0.000187	CcSEcCtD
Lenalidomide—Vomiting—Mycophenolate mofetil—systemic lupus erythematosus	3.97e-05	0.000187	CcSEcCtD
Lenalidomide—Hypersensitivity—Triamcinolone—systemic lupus erythematosus	3.95e-05	0.000186	CcSEcCtD
Lenalidomide—Hypersensitivity—Methylprednisolone—systemic lupus erythematosus	3.94e-05	0.000185	CcSEcCtD
Lenalidomide—Rash—Mycophenolate mofetil—systemic lupus erythematosus	3.94e-05	0.000185	CcSEcCtD
Lenalidomide—Dermatitis—Mycophenolate mofetil—systemic lupus erythematosus	3.94e-05	0.000185	CcSEcCtD
Lenalidomide—Headache—Mycophenolate mofetil—systemic lupus erythematosus	3.91e-05	0.000184	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—systemic lupus erythematosus	3.91e-05	0.000184	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NOS3—systemic lupus erythematosus	3.91e-05	0.00102	CbGpPWpGaD
Lenalidomide—Vertigo—Methotrexate—systemic lupus erythematosus	3.9e-05	0.000183	CcSEcCtD
Lenalidomide—Diarrhoea—Hydrocortisone—systemic lupus erythematosus	3.89e-05	0.000183	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—systemic lupus erythematosus	3.89e-05	0.00102	CbGpPWpGaD
Lenalidomide—Leukopenia—Methotrexate—systemic lupus erythematosus	3.88e-05	0.000183	CcSEcCtD
Lenalidomide—Urticaria—Dexamethasone—systemic lupus erythematosus	3.86e-05	0.000182	CcSEcCtD
Lenalidomide—Urticaria—Betamethasone—systemic lupus erythematosus	3.86e-05	0.000182	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Prednisone—systemic lupus erythematosus	3.86e-05	0.000182	CcSEcCtD
Lenalidomide—Dizziness—Prednisolone—systemic lupus erythematosus	3.85e-05	0.000181	CcSEcCtD
Lenalidomide—Asthenia—Triamcinolone—systemic lupus erythematosus	3.85e-05	0.000181	CcSEcCtD
Lenalidomide—Abdominal pain—Betamethasone—systemic lupus erythematosus	3.84e-05	0.000181	CcSEcCtD
Lenalidomide—Body temperature increased—Dexamethasone—systemic lupus erythematosus	3.84e-05	0.000181	CcSEcCtD
Lenalidomide—Abdominal pain—Dexamethasone—systemic lupus erythematosus	3.84e-05	0.000181	CcSEcCtD
Lenalidomide—Body temperature increased—Betamethasone—systemic lupus erythematosus	3.84e-05	0.000181	CcSEcCtD
Lenalidomide—Asthenia—Methylprednisolone—systemic lupus erythematosus	3.84e-05	0.000181	CcSEcCtD
Lenalidomide—Insomnia—Prednisone—systemic lupus erythematosus	3.83e-05	0.00018	CcSEcCtD
Lenalidomide—Nausea—Cyclosporine—systemic lupus erythematosus	3.8e-05	0.000179	CcSEcCtD
Lenalidomide—Paraesthesia—Prednisone—systemic lupus erythematosus	3.8e-05	0.000179	CcSEcCtD
Lenalidomide—Pruritus—Triamcinolone—systemic lupus erythematosus	3.79e-05	0.000179	CcSEcCtD
Lenalidomide—Cough—Methotrexate—systemic lupus erythematosus	3.78e-05	0.000178	CcSEcCtD
Lenalidomide—Pruritus—Methylprednisolone—systemic lupus erythematosus	3.78e-05	0.000178	CcSEcCtD
Lenalidomide—Dizziness—Hydrocortisone—systemic lupus erythematosus	3.76e-05	0.000177	CcSEcCtD
Lenalidomide—Dyspepsia—Prednisone—systemic lupus erythematosus	3.73e-05	0.000176	CcSEcCtD
Lenalidomide—Nausea—Mycophenolate mofetil—systemic lupus erythematosus	3.71e-05	0.000175	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—systemic lupus erythematosus	3.69e-05	0.000174	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—systemic lupus erythematosus	3.69e-05	0.000174	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—systemic lupus erythematosus	3.69e-05	0.000174	CcSEcCtD
Lenalidomide—Decreased appetite—Prednisone—systemic lupus erythematosus	3.68e-05	0.000173	CcSEcCtD
Lenalidomide—Rash—Prednisolone—systemic lupus erythematosus	3.67e-05	0.000173	CcSEcCtD
Lenalidomide—Dermatitis—Prednisolone—systemic lupus erythematosus	3.67e-05	0.000173	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic lupus erythematosus	3.67e-05	0.000173	CcSEcCtD
Lenalidomide—Diarrhoea—Methylprednisolone—systemic lupus erythematosus	3.66e-05	0.000172	CcSEcCtD
Lenalidomide—Fatigue—Prednisone—systemic lupus erythematosus	3.65e-05	0.000172	CcSEcCtD
Lenalidomide—Headache—Prednisolone—systemic lupus erythematosus	3.65e-05	0.000172	CcSEcCtD
Lenalidomide—Discomfort—Methotrexate—systemic lupus erythematosus	3.65e-05	0.000172	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—systemic lupus erythematosus	3.62e-05	0.000948	CbGpPWpGaD
Lenalidomide—Constipation—Prednisone—systemic lupus erythematosus	3.62e-05	0.000171	CcSEcCtD
Lenalidomide—Vomiting—Hydrocortisone—systemic lupus erythematosus	3.62e-05	0.00017	CcSEcCtD
Lenalidomide—Rash—Hydrocortisone—systemic lupus erythematosus	3.59e-05	0.000169	CcSEcCtD
Lenalidomide—Dermatitis—Hydrocortisone—systemic lupus erythematosus	3.59e-05	0.000169	CcSEcCtD
Lenalidomide—Confusional state—Methotrexate—systemic lupus erythematosus	3.57e-05	0.000168	CcSEcCtD
Lenalidomide—Headache—Hydrocortisone—systemic lupus erythematosus	3.57e-05	0.000168	CcSEcCtD
Lenalidomide—Dizziness—Triamcinolone—systemic lupus erythematosus	3.54e-05	0.000167	CcSEcCtD
Lenalidomide—Dizziness—Methylprednisolone—systemic lupus erythematosus	3.54e-05	0.000166	CcSEcCtD
Lenalidomide—Infection—Methotrexate—systemic lupus erythematosus	3.52e-05	0.000166	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—systemic lupus erythematosus	3.51e-05	0.000918	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—systemic lupus erythematosus	3.5e-05	0.000915	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Prednisone—systemic lupus erythematosus	3.49e-05	0.000164	CcSEcCtD
Lenalidomide—Asthenia—Dexamethasone—systemic lupus erythematosus	3.49e-05	0.000164	CcSEcCtD
Lenalidomide—Asthenia—Betamethasone—systemic lupus erythematosus	3.49e-05	0.000164	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—systemic lupus erythematosus	3.47e-05	0.000163	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—systemic lupus erythematosus	3.47e-05	0.000163	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Prednisone—systemic lupus erythematosus	3.46e-05	0.000163	CcSEcCtD
Lenalidomide—Nausea—Prednisolone—systemic lupus erythematosus	3.46e-05	0.000163	CcSEcCtD
Lenalidomide—Pruritus—Betamethasone—systemic lupus erythematosus	3.44e-05	0.000162	CcSEcCtD
Lenalidomide—Pruritus—Dexamethasone—systemic lupus erythematosus	3.44e-05	0.000162	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—systemic lupus erythematosus	3.44e-05	0.000162	CcSEcCtD
Lenalidomide—Hyperhidrosis—Methotrexate—systemic lupus erythematosus	3.42e-05	0.000161	CcSEcCtD
Lenalidomide—Vomiting—Triamcinolone—systemic lupus erythematosus	3.41e-05	0.00016	CcSEcCtD
Lenalidomide—Vomiting—Methylprednisolone—systemic lupus erythematosus	3.4e-05	0.00016	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CDKN1B—systemic lupus erythematosus	3.39e-05	0.000886	CbGpPWpGaD
Lenalidomide—Nausea—Hydrocortisone—systemic lupus erythematosus	3.38e-05	0.000159	CcSEcCtD
Lenalidomide—Rash—Triamcinolone—systemic lupus erythematosus	3.38e-05	0.000159	CcSEcCtD
Lenalidomide—Dermatitis—Triamcinolone—systemic lupus erythematosus	3.38e-05	0.000159	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—systemic lupus erythematosus	3.37e-05	0.000159	CcSEcCtD
Lenalidomide—Rash—Methylprednisolone—systemic lupus erythematosus	3.37e-05	0.000159	CcSEcCtD
Lenalidomide—Dermatitis—Methylprednisolone—systemic lupus erythematosus	3.37e-05	0.000159	CcSEcCtD
Lenalidomide—Urticaria—Prednisone—systemic lupus erythematosus	3.36e-05	0.000158	CcSEcCtD
Lenalidomide—Headache—Triamcinolone—systemic lupus erythematosus	3.36e-05	0.000158	CcSEcCtD
Lenalidomide—Headache—Methylprednisolone—systemic lupus erythematosus	3.35e-05	0.000158	CcSEcCtD
Lenalidomide—Abdominal pain—Prednisone—systemic lupus erythematosus	3.35e-05	0.000158	CcSEcCtD
Lenalidomide—Body temperature increased—Prednisone—systemic lupus erythematosus	3.35e-05	0.000158	CcSEcCtD
Lenalidomide—Diarrhoea—Dexamethasone—systemic lupus erythematosus	3.33e-05	0.000157	CcSEcCtD
Lenalidomide—Diarrhoea—Betamethasone—systemic lupus erythematosus	3.33e-05	0.000157	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IL2—systemic lupus erythematosus	3.31e-05	0.000867	CbGpPWpGaD
Lenalidomide—Hypotension—Methotrexate—systemic lupus erythematosus	3.31e-05	0.000156	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TGFB1—systemic lupus erythematosus	3.3e-05	0.000862	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—systemic lupus erythematosus	3.22e-05	0.000152	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—TGFB1—systemic lupus erythematosus	3.22e-05	0.000843	CbGpPWpGaD
Lenalidomide—Dizziness—Betamethasone—systemic lupus erythematosus	3.22e-05	0.000151	CcSEcCtD
Lenalidomide—Dizziness—Dexamethasone—systemic lupus erythematosus	3.22e-05	0.000151	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—systemic lupus erythematosus	3.2e-05	0.000151	CcSEcCtD
Lenalidomide—Nausea—Triamcinolone—systemic lupus erythematosus	3.18e-05	0.00015	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—systemic lupus erythematosus	3.18e-05	0.00015	CcSEcCtD
Lenalidomide—Nausea—Methylprednisolone—systemic lupus erythematosus	3.18e-05	0.00015	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—systemic lupus erythematosus	3.16e-05	0.000149	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—systemic lupus erythematosus	3.15e-05	0.000148	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—systemic lupus erythematosus	3.14e-05	0.000822	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MMP9—systemic lupus erythematosus	3.14e-05	0.00082	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN1A—systemic lupus erythematosus	3.12e-05	0.000817	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Prednisone—systemic lupus erythematosus	3.12e-05	0.000147	CcSEcCtD
Lenalidomide—Dyspepsia—Methotrexate—systemic lupus erythematosus	3.12e-05	0.000147	CcSEcCtD
Lenalidomide—Vomiting—Dexamethasone—systemic lupus erythematosus	3.09e-05	0.000146	CcSEcCtD
Lenalidomide—Vomiting—Betamethasone—systemic lupus erythematosus	3.09e-05	0.000146	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—systemic lupus erythematosus	3.08e-05	0.000805	CbGpPWpGaD
Lenalidomide—Decreased appetite—Methotrexate—systemic lupus erythematosus	3.08e-05	0.000145	CcSEcCtD
Lenalidomide—PTGS2—Disease—XRCC6—systemic lupus erythematosus	3.07e-05	0.000803	CbGpPWpGaD
Lenalidomide—Rash—Dexamethasone—systemic lupus erythematosus	3.07e-05	0.000144	CcSEcCtD
Lenalidomide—Rash—Betamethasone—systemic lupus erythematosus	3.07e-05	0.000144	CcSEcCtD
Lenalidomide—Dermatitis—Dexamethasone—systemic lupus erythematosus	3.06e-05	0.000144	CcSEcCtD
Lenalidomide—Dermatitis—Betamethasone—systemic lupus erythematosus	3.06e-05	0.000144	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Methotrexate—systemic lupus erythematosus	3.06e-05	0.000144	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—systemic lupus erythematosus	3.05e-05	0.000144	CcSEcCtD
Lenalidomide—Headache—Betamethasone—systemic lupus erythematosus	3.05e-05	0.000143	CcSEcCtD
Lenalidomide—Headache—Dexamethasone—systemic lupus erythematosus	3.05e-05	0.000143	CcSEcCtD
Lenalidomide—Asthenia—Prednisone—systemic lupus erythematosus	3.04e-05	0.000143	CcSEcCtD
Lenalidomide—Pain—Methotrexate—systemic lupus erythematosus	3.03e-05	0.000142	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—TNF—systemic lupus erythematosus	3.01e-05	0.000787	CbGpPWpGaD
Lenalidomide—Pruritus—Prednisone—systemic lupus erythematosus	3e-05	0.000141	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—EP300—systemic lupus erythematosus	2.97e-05	0.000778	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—systemic lupus erythematosus	2.94e-05	0.000768	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Methotrexate—systemic lupus erythematosus	2.92e-05	0.000137	CcSEcCtD
Lenalidomide—Diarrhoea—Prednisone—systemic lupus erythematosus	2.9e-05	0.000136	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Methotrexate—systemic lupus erythematosus	2.89e-05	0.000136	CcSEcCtD
Lenalidomide—Nausea—Dexamethasone—systemic lupus erythematosus	2.89e-05	0.000136	CcSEcCtD
Lenalidomide—Nausea—Betamethasone—systemic lupus erythematosus	2.89e-05	0.000136	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—systemic lupus erythematosus	2.82e-05	0.000737	CbGpPWpGaD
Lenalidomide—Urticaria—Methotrexate—systemic lupus erythematosus	2.81e-05	0.000132	CcSEcCtD
Lenalidomide—Dizziness—Prednisone—systemic lupus erythematosus	2.8e-05	0.000132	CcSEcCtD
Lenalidomide—Body temperature increased—Methotrexate—systemic lupus erythematosus	2.8e-05	0.000132	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—systemic lupus erythematosus	2.8e-05	0.000132	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—systemic lupus erythematosus	2.71e-05	0.000709	CbGpPWpGaD
Lenalidomide—Vomiting—Prednisone—systemic lupus erythematosus	2.69e-05	0.000127	CcSEcCtD
Lenalidomide—Rash—Prednisone—systemic lupus erythematosus	2.67e-05	0.000126	CcSEcCtD
Lenalidomide—Dermatitis—Prednisone—systemic lupus erythematosus	2.67e-05	0.000126	CcSEcCtD
Lenalidomide—Headache—Prednisone—systemic lupus erythematosus	2.65e-05	0.000125	CcSEcCtD
Lenalidomide—Hypersensitivity—Methotrexate—systemic lupus erythematosus	2.61e-05	0.000123	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—RXRA—systemic lupus erythematosus	2.61e-05	0.000682	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFB1—systemic lupus erythematosus	2.58e-05	0.000676	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—systemic lupus erythematosus	2.58e-05	0.000675	CbGpPWpGaD
Lenalidomide—Asthenia—Methotrexate—systemic lupus erythematosus	2.54e-05	0.00012	CcSEcCtD
Lenalidomide—Nausea—Prednisone—systemic lupus erythematosus	2.52e-05	0.000118	CcSEcCtD
Lenalidomide—Pruritus—Methotrexate—systemic lupus erythematosus	2.5e-05	0.000118	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—systemic lupus erythematosus	2.48e-05	0.00065	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—systemic lupus erythematosus	2.44e-05	0.000639	CbGpPWpGaD
Lenalidomide—Diarrhoea—Methotrexate—systemic lupus erythematosus	2.42e-05	0.000114	CcSEcCtD
Lenalidomide—Dizziness—Methotrexate—systemic lupus erythematosus	2.34e-05	0.00011	CcSEcCtD
Lenalidomide—PTGS2—Disease—HIST2H2AC—systemic lupus erythematosus	2.26e-05	0.000592	CbGpPWpGaD
Lenalidomide—Vomiting—Methotrexate—systemic lupus erythematosus	2.25e-05	0.000106	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic lupus erythematosus	2.24e-05	0.000587	CbGpPWpGaD
Lenalidomide—Rash—Methotrexate—systemic lupus erythematosus	2.23e-05	0.000105	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—systemic lupus erythematosus	2.23e-05	0.000105	CcSEcCtD
Lenalidomide—Headache—Methotrexate—systemic lupus erythematosus	2.22e-05	0.000104	CcSEcCtD
Lenalidomide—PTGS2—Disease—CSK—systemic lupus erythematosus	2.2e-05	0.000577	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—systemic lupus erythematosus	2.2e-05	0.000575	CbGpPWpGaD
Lenalidomide—Nausea—Methotrexate—systemic lupus erythematosus	2.1e-05	9.9e-05	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—systemic lupus erythematosus	2.09e-05	0.000548	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—systemic lupus erythematosus	2.08e-05	0.000545	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD247—systemic lupus erythematosus	2.07e-05	0.000542	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NAT2—systemic lupus erythematosus	2.07e-05	0.000542	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NCF2—systemic lupus erythematosus	2.02e-05	0.000527	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—systemic lupus erythematosus	1.95e-05	0.00051	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—systemic lupus erythematosus	1.92e-05	0.000503	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—systemic lupus erythematosus	1.83e-05	0.000478	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—RXRA—systemic lupus erythematosus	1.76e-05	0.00046	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—systemic lupus erythematosus	1.73e-05	0.000453	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—systemic lupus erythematosus	1.65e-05	0.000431	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic lupus erythematosus	1.59e-05	0.000416	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—JUNB—systemic lupus erythematosus	1.58e-05	0.000414	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—systemic lupus erythematosus	1.48e-05	0.000388	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—systemic lupus erythematosus	1.48e-05	0.000387	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NAT2—systemic lupus erythematosus	1.47e-05	0.000384	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PRL—systemic lupus erythematosus	1.46e-05	0.000381	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—JAK1—systemic lupus erythematosus	1.17e-05	0.000305	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—RXRA—systemic lupus erythematosus	1.16e-05	0.000304	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CCR5—systemic lupus erythematosus	1.1e-05	0.000289	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—systemic lupus erythematosus	1.08e-05	0.000282	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ALB—systemic lupus erythematosus	9.98e-06	0.000261	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD80—systemic lupus erythematosus	9.09e-06	0.000238	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—RXRA—systemic lupus erythematosus	8.23e-06	0.000215	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TYK2—systemic lupus erythematosus	7.67e-06	0.000201	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS3—systemic lupus erythematosus	7.53e-06	0.000197	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—systemic lupus erythematosus	7.33e-06	0.000192	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD4—systemic lupus erythematosus	6.94e-06	0.000181	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALB—systemic lupus erythematosus	6.59e-06	0.000172	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1B—systemic lupus erythematosus	6.52e-06	0.000171	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NOS3—systemic lupus erythematosus	6.3e-06	0.000165	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1A—systemic lupus erythematosus	6.02e-06	0.000157	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EP300—systemic lupus erythematosus	5.73e-06	0.00015	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—systemic lupus erythematosus	5.2e-06	0.000136	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFB1—systemic lupus erythematosus	4.98e-06	0.00013	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—EP300—systemic lupus erythematosus	4.8e-06	0.000125	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALB—systemic lupus erythematosus	4.67e-06	0.000122	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NOS3—systemic lupus erythematosus	4.47e-06	0.000117	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—systemic lupus erythematosus	4.09e-06	0.000107	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—systemic lupus erythematosus	3.75e-06	9.82e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—EP300—systemic lupus erythematosus	3.4e-06	8.9e-05	CbGpPWpGaD
